UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Upstream Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.80+0.04 (+1.45%)
Close on Oct 19, 2026
- Market cap
- $152.79M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
92.3%
51M of 55M shares
Institutional holders
149
38 new, 28 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
0 buys · 15 sales
Net sold $104.80K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 7,936,880 | 14.80% | 13G (passive) amendment | Jun 30, 2025 |
| FMR LLC | 7,176,187 | 13.40% | 13G (passive) amendment | Dec 31, 2024 |
| Access Industries Management, LLC | 5,494,410 | 10.70% | 13D (active) | Oct 15, 2024 |
| OrbiMed Capital GP VIII LLC | 4,554,873 | 8.90% | 13D (active) | Oct 15, 2024 |
| Norges Bank | 4,206,586 | 7.73% | 13G (passive) amendment | Jun 30, 2026 |
| Xiangmin Cui | 3,285,293 | 6.10% | 13G (passive) | Dec 31, 2024 |
| BlackRock, Inc. | 2,814,714 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Chen Yu | 2,801,763 | 5.20% | 13G (passive) | Dec 31, 2024 |
| Decheng Capital Management IV (Cayman), LLC | 2,724,868 | 5.00% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of UPB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 8,162,897 | 14.90% | $56.49M | +61,334 | 0.00% |
| Orbimed Advisors LLC | 5,693,589 | 10.40% | $39.40M | – | 0.73% |
| Norges Bank | 3,768,619 | 6.88% | $26.08M | New | 0.00% |
| BlackRock, Inc. | 3,753,358 | 6.85% | $25.97M | +382,669 | 0.00% |
| Decheng Capital LLC | 2,724,868 | 4.98% | $18.86M | – | 2.58% |
| Enavate Sciences Gp, LLC | 2,459,703 | 4.49% | $17.02M | – | 4.93% |
| Vanguard Capital Management LLC | 1,876,734 | 3.43% | $12.99M | +3,160 | 0.00% |
| Millennium Management LLC | 1,143,775 | 2.09% | $7.91M | +206,452 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,036,044 | 1.89% | $7.17M | +215,564 | 0.00% |
| JPMorgan Chase & Co | 1,012,044 | 1.85% | $7.01M | +549,043 | 0.00% |
| Qube Research & Technologies Ltd | 978,500 | 1.79% | $6.77M | +359,179 | 0.01% |
| Parkman Healthcare Partners LLC | 935,247 | 1.71% | $6.47M | +148,464 | 0.66% |
| Geode Capital Management, LLC | 931,261 | 1.70% | $6.45M | −19,356 | 0.00% |
| SEB Asset Management AB | 878,473 | 1.60% | $6.08M | – | 0.02% |
| Woodline Partners LP | 831,481 | 1.52% | $5.75M | – | 0.02% |
| State Street Corp | 766,323 | 1.40% | $5.30M | +60,973 | 0.00% |
| Vanguard Portfolio Management LLC | 712,667 | 1.30% | $4.93M | −15,044 | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 693,555 | 1.27% | $4.80M | −307,076 | 0.09% |
| Bain Capital Life Sciences Investors, LLC | 600,949 | 1.10% | $4.16M | −266,262 | 0.25% |
| Aqr Capital Management LLC | 544,869 | 0.99% | $3.77M | +472,698 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 51M | 92.3% | 38 / 65 | 28 / 28 | 11M | 5M |
| Q1 2026 | 140 | 45M | 82.0% | 47 / 47 | 35 / 38 | 13M | 17M |
| Q4 2025 | 133 | 51M | 93.4% | 46 / 42 | 33 / 8 | 12M | 5M |
| Q3 2025 | 95 | 44M | 81.2% | 22 / 38 | 22 / 10 | 4M | 8M |
| Q2 2025 | 83 | 48M | 88.3% | 14 / 41 | 13 / 10 | 5M | 3M |
| Q1 2025 | 79 | 46M | 84.5% | 24 / 11 | 26 / 14 | 6M | 1M |
| Q4 2024 | 70 | 42M | 76.8% | 70 / 0 | 0 / 0 | 42M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of UPB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,443,025 | 2.63% | $9.99M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,371,372 | 2.50% | $8.65M | 0.10% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,321,800 | 2.41% | $8.34M | 0.11% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 965,800 | 1.76% | $6.09M | 0.13% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 921,063 | 1.68% | $6.37M | 0.01% | Jun 30, 2026 |
| Select Health Care Portfolio | 800,000 | 1.46% | $6.69M | 0.12% | May 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 693,618 | 1.27% | $4.38M | 0.10% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 691,003 | 1.26% | $4.36M | 0.20% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 400,000 | 0.73% | $2.52M | 0.08% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 386,877 | 0.71% | $2.68M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 384,509 | 0.70% | $2.43M | 0.01% | Jul 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 341,675 | 0.62% | $2.86M | 0.05% | May 29, 2026 |
| iShares Russell 2000 Value ETF | 338,261 | 0.62% | $2.34M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 256,130 | 0.47% | $1.77M | 0.02% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 234,657 | 0.43% | $1.96M | 0.04% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Everett Rand Sutherland | Chief Executive Officer, Director | 68,717 | 0.13% | Sep 17, 2026 |
| Aaron Deykin | Chief Medical Officer | 32,302 | 0.06% | Sep 17, 2026 |
| Allison Ambrose | General Counsel | 15,563 | 0.03% | Sep 17, 2026 |
| Michael Gray | CFO and COO | 27,942 | 0.05% | Sep 17, 2026 |
| Adam Houghton | Chief Business Officer | 22,901 | 0.04% | Sep 17, 2026 |
| Erez Chimovits | Director | 4,554,873 | 8.32% | Jun 11, 2026 |
| Harold Edward Fleming | Director | – | – | Jun 11, 2026 |
| Liam Ratcliffe | Director | – | – | Jun 11, 2026 |
| Marcella K. Ruddy | Director | – | – | Jun 11, 2026 |
| Ronald C. Renaud JR | Director | – | – | Jun 11, 2026 |
| Daniella Beckman | Director | – | – | Jun 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adam Houghton Chief Business Officer | Sep 16, 2026 | Sale | −700 | $5.49 | $3.84K | 22,901 |
| Michael Gray CFO and COO | Sep 16, 2026 | Sale | −853 | $5.49 | $4.68K | 27,942 |
| Allison Ambrose General Counsel | Sep 16, 2026 | Sale | −485 | $5.49 | $2.66K | 15,563 |
| Aaron Deykin Chief Medical Officer | Sep 16, 2026 | Sale | −895 | $5.49 | $4.91K | 32,302 |
| Everett Rand Sutherland Chief Executive Officer, Director | Sep 16, 2026 | Sale | −2,095 | $5.49 | $11.50K | 68,717 |
| Michael Gray CFO and COO | Jun 16, 2026 | Sale | −853 | $6.10 | $5.20K | 28,795 |
| Aaron Deykin Chief Medical Officer | Jun 16, 2026 | Sale | −895 | $6.10 | $5.46K | 33,197 |
| Allison Ambrose General Counsel | Jun 16, 2026 | Sale | −477 | $6.10 | $2.91K | 16,048 |
| Adam Houghton Chief Business Officer | Jun 16, 2026 | Sale | −700 | $6.10 | $4.27K | 23,601 |
| Everett Rand Sutherland Chief Executive Officer, Director | Jun 16, 2026 | Sale | −2,095 | $6.10 | $12.78K | 70,812 |
| Everett Rand Sutherland Chief Executive Officer, Director | Mar 16, 2026 | Sale | −2,093 | $9.29 | $19.44K | 72,907 |
| Aaron Deykin Chief Medical Officer | Mar 16, 2026 | Sale | −894 | $9.29 | $8.31K | 32,687 |
| Michael Gray CFO and COO | Mar 16, 2026 | Sale | −852 | $9.29 | $7.92K | 29,648 |
| Adam Houghton Chief Business Officer | Mar 16, 2026 | Sale | −699 | $9.29 | $6.49K | 24,301 |
| Allison Ambrose General Counsel | Mar 16, 2026 | Sale | −475 | $9.29 | $4.41K | 16,525 |
| Everett Rand Sutherland Chief Executive Officer, Director | Jan 2, 2026 | Award | +75,000 | – | – | 75,000 |
| Allison Ambrose General Counsel | Jan 2, 2026 | Award | +17,000 | – | – | 17,000 |
| Adam Houghton Chief Business Officer | Jan 2, 2026 | Award | +25,000 | – | – | 25,000 |
| Michael Gray CFO and COO | Jan 2, 2026 | Award | +30,500 | – | – | 30,500 |
| Aaron Deykin Chief Medical Officer | Jan 2, 2026 | Award | +32,000 | – | – | 33,581 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Buy | +660,000 | $17.00 | $11.22M | 4,554,873 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Conversion | +2,887,833 | – | – | 3,894,873 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Buy | +165,000 | $17.00 | $2.81M | 1,138,716 |
| Erez Chimovits Director, 10% owner | Oct 15, 2024 | Conversion | +721,956 | – | – | 973,716 |
| Industries Holdings LLC Access 10% owner | Oct 15, 2024 | Conversion | +1,172,410 | – | – | 5,494,410 |
| Industries Holdings LLC Access 10% owner | Oct 15, 2024 | Conversion | +3,147,000 | – | – | 4,322,000 |
| Industries Holdings LLC Access 10% owner | Oct 15, 2024 | Buy | +1,175,000 | $17.00 | $19.98M | 1,175,000 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Buy | +660,000 | $17.00 | $11.22M | 4,554,873 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Conversion | +721,956 | – | – | 973,716 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Buy | +165,000 | $17.00 | $2.81M | 1,138,716 |
| Advisors Llc Orbimed Director, 10% owner | Oct 15, 2024 | Conversion | +2,887,833 | – | – | 3,894,873 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington 10% owner | Oct 15, 2024 | Conversion | +894,733 | – | – | 894,733 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.